STAT Plus: 9 things to know about Alkermes and its controversial drug for treatment-resistant depression
APSTOCK
The FDA is bringing together a panel of outside experts to review a novel and controversial drug for treatment-resistant depression.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario